+++ title = "生命工学" description = "ライフエンジニアリングとは、科学的および技術的アプローチを適用して、新しい機能、特性、または能力を備えた人工生命体または生物学的システムを意図的に設計および構築することを指します。これには、自然界に存在しないまったく新しい生命体の出現をもたらす、遺伝物質の意図的な操作と生物学的構成要素の集合が含まれます。" template = "wiki-page.html" toc = true [extra] category = "Science & Technology" editorial_pass = "2026-05" entry_type = "discipline" claim_type = "direct" alternative_names = ["Engineering biology", "Designer biology", "Constructive biology", "Bioengineering of life", "Living-systems engineering"] [extra.infobox] type = "Engineering discipline applied to living systems" principal_sub_disciplines = "Genetic engineering; synthetic biology; synthetic genomics; xenobiology" adjacent_fields = "Bioinformatics; systems biology; metabolic engineering; protein engineering; directed evolution; cell-free biology; biocomputing; tissue engineering" key_capability = "Reading, writing, and editing DNA; designing organisms and biological subsystems at the genetic and molecular level" foundational_milestones = "First recombinant DNA (Berg, Boyer, Cohen — 1972–73); first commercial recombinant pharmaceutical (Humulin, 1982); first complete genome sequence (1995); first cell with synthetic genome (JCVI-syn1.0, 2010); first minimal synthetic cell (JCVI-syn3.0, 2016); CRISPR–Cas9 (Doudna and Charpentier, 2012); first CRISPR gene therapy approval (Casgevy, 2023)" current_status = "Active and rapidly developing scientific and industrial field; capability expanding by orders of magnitude per decade" framework_significance = "The contemporary terrestrial development of the capability the source material attributes to the Elohim civilization; on the framework, the most concrete convergence between source-predicted and observed human development in the Aquarian period" +++ **Life engineering** is the application of scientific and engineering methods to the deliberate design and construction of living organisms or biological systems with novel functions, characteristics, or capabilities. It is a contemporary scientific and industrial field, in active development since the early 1970s and expanding rapidly across the 2010s and 2020s. The term is used as an umbrella for several closely related disciplines — most prominently *genetic engineering*, *synthetic biology*, *synthetic genomics*, and *xenobiology* — that share the common project of treating living matter as something that can be designed at the molecular level rather than only observed and described. The discipline's central technical capability is the ability to read, write, and edit DNA. Reading capacity — the sequencing of existing genomes — has improved by approximately ten orders of magnitude in cost and throughput since the first complete genome (a bacteriophage) was sequenced in 1977; the human genome, which cost approximately three billion United States dollars and required thirteen years to sequence between 1990 and 2003, can now be sequenced for several hundred dollars in a single working day. Writing capacity — the chemical synthesis of DNA from its molecular components — has improved comparably, with megabase-scale synthesis routinely available from commercial suppliers and the cost-per-base falling by roughly half each year across the past two decades. Editing capacity, transformed by the development of the CRISPR–Cas systems from 2012 onward, has reached a level of precision and accessibility that has made directed modification of genomes — including the human genome, in approved clinical applications — a routine laboratory technique. The combination of these three capabilities — read, write, edit — defines the operational floor of contemporary life engineering as a practical engineering discipline rather than a theoretical aspiration. The term *life engineering* is not the standard disciplinary name within the academic literature, where *synthetic biology* is the more common label for the field's most ambitious wing. The Wheel of Heaven corpus uses *life engineering* as a broader umbrella term, since the framework's interest is not in any single sub-discipline but in the integrated capability of designing and synthesising biological systems — a capability that is distributed across genetic engineering, synthetic biology, synthetic genomics, xenobiology, and several adjacent fields. The corpus treats these as the operational components of the same emerging human capacity. The treatment below describes the field as a contemporary scientific reality with attribution to the relevant scientific literature throughout; the framework's reading of that reality is registered in a separate section at the end of the entry. The reading on which the framework's interest in life engineering depends is not contested. The scientific reality of the field — its techniques, its achievements, its commercial and clinical deployments — is established and documented across a substantial scientific literature. What is contested is the framework's interpretation of the field's emergence: the claim that the contemporary development of life engineering is the present-day local instance of a capability the source material attributes to the Elohim civilization in deep antiquity. The corpus presents the field accurately as it currently stands, registers the framework's reading of its significance, and treats the broader interpretive question with the same epistemic discipline applied throughout the wiki. ## Definition and scope The boundaries of "life engineering" as a unified concept are contested within the relevant scientific communities and the term is used with somewhat different scopes by different authors. A brief survey of the principal usages clarifies what the corpus means by the term in this entry. ### As an umbrella discipline The broadest usage treats life engineering as the unified discipline that encompasses any deliberate scientific intervention in the structure or function of living systems for the purpose of producing systems with predetermined properties. On this usage, life engineering includes the work of selective breeding (which has been practised for at least ten thousand years), the work of classical genetics and biochemistry (which made the molecular substrates of biological function legible to laboratory study across the twentieth century), the work of genetic engineering (which made those substrates editable), and the work of synthetic biology and synthetic genomics (which made them designable from scratch). On this umbrella usage, life engineering is the long arc of the human relationship to biological design, from the domestication of wheat to the synthesis of minimal cells. ### As the contemporary engineering discipline A narrower and more common usage restricts "life engineering" or "engineering biology" to the recent and currently active discipline that explicitly treats biological systems with engineering-discipline methods: modularity, standardisation, abstraction, characterisation, predictable composition, and design–build–test cycles. This usage corresponds approximately to what is more commonly called *synthetic biology* in the academic literature, and centres on the post-2000 effort to bring genuine engineering-discipline practices to bear on the design of biological systems whose evolved complexity has historically resisted such practices. ### As applied to biotechnology and industrial bioproduction A third usage, common in industrial and commercial contexts, treats life engineering as the applied discipline that uses engineered organisms — bacteria, yeasts, mammalian cell lines, and others — as production platforms for pharmaceuticals, biofuels, food ingredients, industrial chemicals, and other commercially valuable products. This usage emphasises the practical applications over the foundational science and is most closely associated with the biotech industry. ### The usage adopted in this entry The corpus adopts the umbrella usage in its broadest form, with particular attention to the post-1973 developments that constitute the field's modern phase. This breadth is deliberate. The framework's interest is in the convergence between contemporary human capability and the capability the source material attributes to the Elohim, and this convergence is most legibly captured at the level of the integrated multi-disciplinary capacity rather than at the level of any single sub-field. The entry's treatment is therefore organised around the four principal sub-disciplines (genetic engineering, synthetic biology, synthetic genomics, xenobiology), with attention to their distinct contributions to the unified life-engineering enterprise. ## Historical development Life engineering as a coherent field begins in the early 1970s, almost exactly coincident with the publication of the Raëlian source material that the Wheel of Heaven corpus reads as its principal textual basis. The chronological coincidence is part of what the framework's reading attends to in its dedicated section below; the historical development itself is set out here without commentary. ### Foundations: the molecular biology of the mid-twentieth century The substrate on which all subsequent life engineering operates is the molecular biology of the mid-twentieth century. The principal foundational discoveries: - **1944** — Avery, MacLeod, and McCarty identify DNA as the carrier of genetic information, displacing the previous protein-based theories of heredity. - **1953** — James Watson and Francis Crick, working from the X-ray crystallography of Rosalind Franklin and Maurice Wilkins, publish the double-helix structure of DNA in *Nature* — establishing the molecular geometry that explains both heredity and replication and that defines the substrate of all subsequent life engineering. - **1958** — Francis Crick formulates the *central dogma* of molecular biology: information flows from DNA to RNA to protein. - **1961** — The genetic code is broken: the correspondence between three-nucleotide codons and amino acids is worked out by Nirenberg, Khorana, Holley, and others over the subsequent few years. - **1968–69** — Werner Arber, Hamilton Smith, and Daniel Nathans identify restriction enzymes — bacterial enzymes that cut DNA at specific sequences — providing the first tool for the targeted manipulation of DNA molecules. - **1970** — Howard Temin and David Baltimore independently discover reverse transcriptase, the enzyme that synthesises DNA from an RNA template — completing the toolkit needed for the in vitro manipulation of genetic information. By the early 1970s, the molecular substrate of life was understood, the genetic code was deciphered, and the principal enzymatic tools for the laboratory manipulation of DNA were in hand. The stage was set for the foundational interventions that would inaugurate the field. ### 1972–1973: the foundational interventions The years 1972 and 1973 contain the foundational events of the field. **Paul Berg** at Stanford, working with Janet Mertz and others, produced the first recombinant DNA molecule in 1972 — joining DNA from the bacterial virus lambda phage with DNA from the monkey virus SV40 using restriction enzymes and DNA ligase. Berg's experiment was a proof of principle but stopped at the molecule itself; Berg himself, recognising the potential biosafety implications, declined to propagate the recombinant molecule in living cells. The propagation step was taken in 1973 by **Herbert Boyer** at the University of California, San Francisco, and **Stanley Cohen** at Stanford. Their experiment combined a plasmid (a small circular DNA molecule that replicates independently in bacteria) with foreign DNA cut by the restriction enzyme EcoRI, ligated the recombinant molecule together, and transformed it into *Escherichia coli* — where it replicated, was inherited by daughter cells, and expressed its encoded proteins. The Boyer–Cohen experiment is conventionally dated as the founding of genetic engineering as a working laboratory discipline. Its publication came in November 1973. The convergence of dates with the Raëlian source material is precise to the month. Claude Vorilhon's first reported contact with Yahweh occurred at Clermont-Ferrand on **13 December 1973** — within weeks of the Boyer–Cohen publication. *Le Livre qui dit la vérité*, the first volume of the Raëlian source material, was published in 1974. The pace of the field thereafter: - **1975** — The Asilomar Conference on Recombinant DNA brings together scientists from around the world to discuss biosafety; the resulting voluntary moratorium and subsequent guidelines establish the regulatory framework for the new field. - **1977** — Frederick Sanger develops dideoxy chain-termination sequencing, the first practical DNA sequencing method; Allan Maxam and Walter Gilbert independently develop a chemical sequencing method. The complete genome of bacteriophage φX174 is sequenced — the first complete genome of any organism. - **1978** — The biotechnology company Genentech, founded in 1976 by Boyer and Robert Swanson, produces human insulin in *E. coli* — the first commercial demonstration of recombinant protein production. - **1982** — Eli Lilly's Humulin, the recombinant human insulin developed in partnership with Genentech, becomes the first commercial product of genetic engineering approved for medical use. The conventional pharmaceutical industry, accustomed to extracting insulin from animal pancreases, is reorganised by this single product. - **1983** — The first transgenic plants (engineered tobacco) are produced by groups including Mary-Dell Chilton's at Washington University. - **1985** — Kary Mullis develops the polymerase chain reaction (PCR), the technique that allows specific DNA sequences to be amplified billions-fold in a few hours — transforming both research and applied molecular biology. - **1990–2003** — The Human Genome Project produces the first complete sequence of the human genome, at a cost of approximately three billion United States dollars across thirteen years of work by an international consortium. - **1996** — The yeast *Saccharomyces cerevisiae* becomes the first eukaryotic organism with a fully sequenced genome. ### 2000s: the formalisation of synthetic biology The early 2000s mark the formalisation of synthetic biology as a named field with its own conferences, journals, institutional structures, and engineering-discipline ambitions. - **2000** — Michael Elowitz and Stanislas Leibler publish the *repressilator*, a designed three-gene oscillator in *E. coli* that produced predictable periodic gene expression — one of the first explicit demonstrations of designed-from-scratch biological circuitry. Jim Collins and colleagues simultaneously publish the *genetic toggle switch*, a bistable two-gene system. The two papers, both in *Nature* in January 2000, are commonly identified as the inaugural publications of contemporary synthetic biology. - **2002** — Eckard Wimmer and colleagues at SUNY Stony Brook synthesise a functional poliovirus from mail-ordered DNA fragments — the first synthesis of a complete viral genome from scratch and the first demonstration that a living pathogen could be assembled from publicly available sequence information and commercial DNA synthesis. - **2003** — Tom Knight at MIT proposes the *BioBricks* standard, a system of standardised genetic parts designed for predictable composition. The Standard Biological Parts Registry is established the same year. - **2004** — The first International Conference on Synthetic Biology is held at MIT; the iGEM (International Genetically Engineered Machine) competition is established as an annual undergraduate synthetic-biology competition. The field is named. - **2005** — Jay Keasling and colleagues at UC Berkeley publish work toward engineering yeast to produce artemisinic acid — a precursor of the antimalarial drug artemisinin — through a multi-gene synthetic pathway. The work, commercialised through Amyris over the subsequent decade, becomes one of the field's flagship demonstrations of metabolic engineering at industrial scale. - **2008** — Daniel Gibson and colleagues at the J. Craig Venter Institute publish the synthesis and assembly of the complete *Mycoplasma genitalium* genome from chemically synthesised oligonucleotides — the largest synthetic genome assembled to date and the precursor to the JCVI-syn1.0 work. ### 2010–present: synthetic genomics, CRISPR, and the commercial maturation The 2010s and 2020s contain the field's most consequential single technical and commercial developments. - **2010** — Daniel Gibson and the JCVI team publish *Mycoplasma mycoides* JCVI-syn1.0 in *Science* — the first organism with an entirely synthetic genome. The 1.08-megabase genome is chemically synthesised, assembled in yeast, transplanted into a *Mycoplasma capricolum* recipient cell, and replicates as a free-living bacterium. The genome contains synthetic "watermarks" — encoded text including the names of the project's contributors and several literary quotations — encoded in non-coding regions of the synthetic chromosome. - **2012** — Jennifer Doudna and Emmanuelle Charpentier publish, in *Science*, the mechanism of the CRISPR–Cas9 system as a programmable DNA-cleavage tool. The publication transforms genome editing from a laborious specialty technique (using zinc-finger nucleases or TALENs) to a routine and inexpensive method accessible to any molecular biology laboratory. Doudna and Charpentier share the 2020 Nobel Prize in Chemistry for the work. - **2013** — Feng Zhang and George Church groups demonstrate CRISPR-mediated editing of human cells; the technology's clinical potential becomes immediately apparent. - **2016** — Clyde Hutchison, Daniel Gibson, J. Craig Venter, and colleagues publish JCVI-syn3.0 — a minimal synthetic cell with 473 genes and a genome of 531 kilobases. The organism is the smallest genome of any free-living organism; approximately 30 percent of its genes have functions that remain uncharacterised at the time of publication. The work establishes the contemporary benchmark for synthetic minimal life. - **2018** — He Jiankui announces in November the birth of twin girls whose embryos were edited with CRISPR to disable the *CCR5* gene — the first human germline editing performed in a clinical context. The work is widely condemned by the international scientific community; He is subsequently imprisoned in China. - **2020** — mRNA vaccine platforms (Pfizer/BioNTech BNT162b2; Moderna mRNA-1273) are deployed at planetary scale during the COVID-19 pandemic. The vaccines are products of a thirty-year development arc in mRNA-as-therapeutic technology and demonstrate the planetary deployment capacity of contemporary life engineering in real time. - **2021** — Pelletier and colleagues publish JCVI-syn3A, a stabilised derivative of syn3.0 with 19 additional genes that restore normal cell division. JCVI-syn3A becomes the working chassis for the broader synthetic-minimal-cell research community, with more than forty laboratories worldwide using the platform. - **2023** — Casgevy (exagamglogene autotemcel), a CRISPR-based gene therapy for sickle-cell disease and transfusion-dependent beta-thalassaemia, is approved by the United Kingdom MHRA in November 2023 and by the United States FDA in December 2023 — the first regulatory approval of a CRISPR-based therapeutic in any jurisdiction. - **2024–present** — The pace continues. AI-driven protein design (David Baker's work on RFdiffusion and related methods, recognised with the 2024 Nobel Prize in Chemistry), advanced base-editing and prime-editing technologies, the expansion of CRISPR therapies into clinical trials for additional indications, and the continued development of synthetic-genome platforms are all under active development. The arc from 1973 to the present is approximately fifty years. The development from the laboratory curiosity of recombinant DNA to a globally deployed and rapidly maturing engineering discipline has occurred within a single human generation. The accelerating pace — orders of magnitude of improvement in reading, writing, and editing capacity per decade — is one of the structural features of the field that the framework's reading attends to. ## The principal sub-disciplines Four sub-disciplines together constitute what this entry calls life engineering. They overlap substantially and the boundaries between them are contested within the field itself; each is treated in turn below, with attention to its distinctive methods, achievements, and current state. ### Genetic engineering Genetic engineering is the modification of an organism's existing genome through the addition, deletion, or alteration of specific genetic sequences. It is the oldest of the four sub-disciplines and the one with the deepest history of commercial and clinical deployment. The field's foundational technical achievement was the 1973 Boyer–Cohen demonstration that recombinant DNA could be introduced into a living bacterial cell and inherited stably across cell divisions. The discipline expanded across the 1970s and 1980s with the development of increasingly sophisticated cloning vectors (plasmids, bacteriophage lambda derivatives, cosmids, bacterial artificial chromosomes, yeast artificial chromosomes), the development of techniques for the directed mutation of specific positions in cloned genes (site-directed mutagenesis, developed by Michael Smith in 1978), and the development of methods for introducing recombinant DNA into eukaryotic cells (microinjection, electroporation, biolistic delivery, and various viral vectors). The 1990s and 2000s saw the development of *gene targeting* — the use of homologous recombination to make specific changes at specific positions in the genome of a living cell — culminating in the production of *knockout mice* (mice with specific genes deleted) that became standard laboratory tools across biomedical research. Mario Capecchi, Martin Evans, and Oliver Smithies shared the 2007 Nobel Prize in Physiology or Medicine for the development of gene targeting in mice. The 2010s transformed the field through CRISPR–Cas9 and subsequent editing technologies. Earlier methods of genome editing (zinc-finger nucleases, developed in the 1990s; TALENs, developed in 2009–2010) had demonstrated the principle of targeted genome modification but required laborious protein engineering for each new target site. CRISPR–Cas9 replaced the protein-engineering step with the simple specification of a short guide-RNA sequence, reducing the time required to design and test a new genome edit from months to days and the cost from tens of thousands of dollars to a few hundred. The combination of accessibility, precision, and cost has produced a transformation of the editing side of the field comparable to what PCR produced for the amplification side in the late 1980s. Subsequent developments have refined the technology. *Base editing*, developed by David Liu and colleagues from 2016 onward, permits the conversion of one DNA base to another at a specific position without inducing a double-strand break — a more precise and less risky form of editing for clinical applications. *Prime editing*, also from the Liu group (2019), permits the insertion or deletion of arbitrary short sequences with high precision. *CRISPR interference* (CRISPRi) and *CRISPR activation* (CRISPRa), developed by the Doudna and Weissman groups and others, permit the silencing or activation of specific genes without modifying the DNA sequence. The contemporary state of genetic engineering as a practical discipline: - **In medicine** — Recombinant proteins (insulin, human growth hormone, erythropoietin, monoclonal antibodies of all classes, blood-clotting factors, interferons, and a growing list of others) produced in engineered bacteria, yeast, or mammalian cell lines constitute a large fraction of modern pharmacology. Gene therapies (using engineered viral vectors to deliver therapeutic genes to patient cells) are approved for several inherited diseases. CAR-T cell therapies (autologous T-cells engineered to recognise tumour antigens) are approved for several haematological cancers. CRISPR-based therapies (Casgevy and several in clinical trial) are at the leading edge of contemporary genetic medicine. - **In agriculture** — Transgenic crops engineered for herbicide tolerance (Roundup-Ready varieties), insect resistance (Bt-expressing varieties), drought tolerance, virus resistance, or nutritional fortification (Golden Rice with engineered beta-carotene synthesis) occupy a large fraction of global commercial cropland. Engineered livestock (AquAdvantage salmon with accelerated growth; pigs engineered for organ donation to humans) are at various regulatory stages. - **In industrial production** — Engineered microorganisms produce a substantial fraction of industrial enzymes, food ingredients (engineered Saccharomyces strains for industrial brewing and baking; *Komagataella phaffii* strains producing animal-protein equivalents for the alternative-protein industry), bioplastics, fine chemicals, and an expanding range of materials. The dedicated treatment lives in the [Genetic engineering](../genetic-engineering/) entry. ### Synthetic biology Synthetic biology is the engineering-discipline branch of life engineering: it treats biological components — genes, proteins, regulatory circuits, metabolic pathways, whole organisms — as modular parts that can be standardised, characterised, and recombined into novel systems with predictable behaviour. The field is distinguished from genetic engineering by its programmatic commitment to genuine engineering-discipline practice rather than the empirical case-by-case approach that has characterised most genetic engineering historically. The field's formative ambition is articulated in the *Engineering Biology* manifesto and related documents from the early 2000s: that biology should become an engineering discipline in the same sense that mechanical engineering, electrical engineering, and software engineering are engineering disciplines — with standardised parts, predictable composition rules, formal design methodologies, and design–build–test cycles that scale. The ambition has been partially realised. Biological systems remain far less predictable than electronic systems; the parts catalogue is far smaller; the composition rules are far less well understood. But the trajectory has been forward and the field has produced an impressive cumulative set of achievements. The intellectual foundations of synthetic biology include the *cybernetics* tradition of the mid-twentieth century, which provided the conceptual vocabulary for treating biological systems as information-processing systems; the *systems biology* tradition of the 1990s and 2000s, which provided the experimental and computational tools for characterising biological systems at the network level; and the *molecular biology* tradition of the post-1973 period, which provided the molecular substrate for any practical implementation. The principal contemporary research programmes within synthetic biology include: - **Genetic circuit engineering** — The design of gene-regulatory networks with specific behavioural properties (oscillators, switches, logic gates, feedback controllers, memory elements). The repressilator, the toggle switch, and a growing catalogue of designed circuits demonstrate the feasibility of designing biological systems whose behaviour can be predicted from the design. - **Metabolic engineering** — The design of multi-gene biosynthetic pathways in microbial hosts for the production of specific molecules. Keasling's artemisinin pathway is the field's flagship demonstration; subsequent work has produced microbial production of opioids, cannabinoids, vanillin, saffron-derived compounds, and an expanding list of other valuable molecules previously sourced from rare or difficult plants. - **Cell-free synthetic biology** — The reconstitution of biological function in cell-free extracts, with the goal of providing simpler and more controllable systems than living cells permit. Cell-free systems are increasingly used for rapid prototyping of designed circuits and pathways. - **Mammalian and human cell engineering** — The application of synthetic-biology methods to mammalian cells, including the engineering of CAR-T cells, the design of cell-based therapeutics, and the development of synthetic gene circuits operating in human cells. - **Synthetic developmental biology** — The application of synthetic-biology methods to the question of how organised multicellular structures emerge from interactions among individual cells. The field is in its early stages but has produced striking demonstrations including synthetic morphogenesis (designed cell–cell signalling producing organised tissue-like structures) and the *Xenobot* work of Levin and colleagues (multicellular organisms assembled from frog cells with computer-designed body plans). The dedicated treatment lives in the [Synthetic biology](../synthetic-biology/) entry. ### Synthetic genomics Synthetic genomics is the construction of complete genomes from chemically synthesised DNA — the most ambitious wing of life engineering and the one most directly comparable to the source material's account of the Elohim's work. Where genetic engineering modifies existing genomes and synthetic biology designs sub-systems within existing organisms, synthetic genomics constructs the genome itself, from the ground up, from designed sequence. The field's principal achievements have been the products of the J. Craig Venter Institute and its collaborators across the 2000s and 2010s. **JCVI-syn1.0** (2010) was the first organism whose genome had been entirely synthesised from chemical reagents. The project synthesised the 1.08-megabase *Mycoplasma mycoides* genome from approximately one thousand short oligonucleotides, assembled the oligonucleotides through hierarchical recombination in *E. coli* and yeast, and transplanted the completed synthetic genome into a *Mycoplasma capricolum* recipient cell from which the native genome had been removed. The resulting organism was a free-living bacterium whose every base of DNA had been chemically synthesised in the laboratory — the first such organism in the history of life on Earth. The genome contained synthetic watermarks: encoded text including the names of the forty-six project contributors, a URL, and three literary quotations (from James Joyce, Robert Oppenheimer quoting Bhagavad Gita, and Richard Feynman). The watermark feature, beyond its symbolic significance, served as proof that the genome was genuinely the synthetic version rather than a wild-type contaminant. **JCVI-syn3.0** (2016) was a minimal synthetic cell with 473 genes and a genome of 531 kilobases — less than half the size of the syn1.0 genome and the smallest known genome of any free-living organism. The project's design proceeded by iterative reduction: genes were progressively removed from the syn1.0 platform and the resulting organisms tested for viability, with non-essential genes identified and removed until further reductions produced non-viable cells. The result was a minimal cell whose every gene was required for survival in laboratory growth media. Approximately 30 percent of the genes in syn3.0 had functions that were uncharacterised at the time of publication — an indication of how much remains to be learned about the molecular basis of even minimal cellular life. **JCVI-syn3A** (2021), reported by Pelletier and colleagues, is a stabilised derivative of syn3.0 with 19 additional genes that restore normal cell division behaviour. The syn3.0 cells, while viable, exhibited pleomorphic (irregular) cellular forms that made them difficult to work with; syn3A cells divide normally and provide a stable working platform for further investigation of the molecular basis of cellular life. The syn3A platform is currently in use at more than forty laboratories worldwide and serves as the contemporary chassis for the minimal-cell research community. **JCVI-syn3B** is a further derivative used in studies of host-microbe interaction, particularly the interaction of minimised bacterial cells with mammalian cells in coculture. Both syn3A and syn3B continue under active investigation. Beyond the JCVI line, synthetic genomics has produced significant work on synthetic eukaryotic genomes. The international *Synthetic Yeast 2.0* (Sc2.0) consortium has been working since the early 2010s on the synthesis of a complete redesigned genome for the yeast *Saccharomyces cerevisiae*. The project has involved the synthesis of individual chromosomes (synI through synXVI) by participating laboratories worldwide and the integration of all sixteen synthetic chromosomes into a single yeast strain. Reports across 2023–2024 describe substantial progress toward the complete synthetic yeast genome. The relevance of synthetic genomics to the framework is direct. The source material describes the Elohim's principal capability as the design and synthesis of complete organisms from designed genetic sequence — beginning at the molecular level and assembling the synthesised genome into a functional cell that propagates through ordinary biological reproduction. Contemporary synthetic genomics, at the scale of single-cell organisms, is the realisation of this capability at the lower bound. The Elohim's version, on the source's account, operates at species- and ecosystem-scale, with multicellular organisms designed and synthesised. Contemporary terrestrial synthetic genomics has not yet reached multicellular scale and the trajectory to that scale is uncertain, but the foundational capability — DNA designed and synthesised, assembled into functional cells, propagating through natural reproduction — is now established. The dedicated treatment lives in the [Synthetic genomics](../synthetic-genomics/) entry. ### Xenobiology Xenobiology is the construction of biological systems that use components — nucleic acids, amino acids, biochemical building blocks — outside the standard set used by terrestrial life. Where genetic engineering, synthetic biology, and synthetic genomics work within the existing molecular toolkit of terrestrial biology (the four DNA bases, the twenty standard amino acids, the standard biochemical pathways), xenobiology asks which features of terrestrial biology are necessary properties of *any* possible biology and which are merely contingent features of the specific lineage that happens to have colonised Earth. The field's principal research programmes include: - **Unnatural base pairs** — The design and synthesis of synthetic DNA bases that pair with one another but not with the natural A–T and G–C pairs, expanding the genetic alphabet from four letters to six or more. Floyd Romesberg's work at Scripps from the late 2000s onward produced functional unnatural base pairs (notably the *dNaM-dTPT3* pair) that can be incorporated into bacterial genomes, replicated through cell division, and used to encode unnatural amino acids in synthesised proteins. The Romesberg group's 2014 demonstration of *Escherichia coli* with a stably maintained six-letter genome was a foundational achievement. - **Xeno-nucleic acids (XNAs)** — Synthetic information-carrying polymers built on chemical scaffolds other than the natural ribose-phosphate backbone of DNA and RNA. Holliger and colleagues at the MRC Laboratory of Molecular Biology in Cambridge demonstrated in 2012 that several XNAs (including HNA, CeNA, ANA, and FANA) could store genetic information and undergo evolution under laboratory selection — establishing that the information-carrying function of nucleic acids is not specific to the natural ribose-phosphate backbone. - **Unnatural amino acids** — The incorporation of synthetic amino acids beyond the standard twenty into engineered proteins, expanding the chemical repertoire of protein engineering. The Schultz laboratory and others have developed methods for the incorporation of more than one hundred different unnatural amino acids into proteins in living cells. - **Genetic code recoding** — The systematic reassignment of genetic codons to encode different amino acids than they would in standard biology. Notable work includes the construction of *E. coli* strains in which specific codons have been removed from the entire genome (the Church and Isaacs *rE.coli* / *Syn61* work) and replaced with codons reassigned to encode unnatural amino acids. The relevance of xenobiology to questions of biology beyond Earth is direct. If life on other worlds exists, it may or may not use the same molecular toolkit as terrestrial life; xenobiology provides the laboratory framework within which to investigate which features are universal and which contingent. The field is also closely connected to the *astrobiology* literature on what life on other worlds might look like and the conditions under which alternative chemistries could support biological function. The framework's interest in xenobiology is less direct than its interest in synthetic genomics, since the source material does not describe the Elohim as using non-standard biochemistry. But the field's broader significance — establishing that the molecular substrate of life on Earth is one possibility among many — is relevant to the framework's reading of the cosmic chain. If creator civilisations exist that have produced multiple humanities on multiple worlds, the question of whether those humanities share Earth's molecular biology or differ in their basic chemistry is one that xenobiology is uniquely positioned to inform. The dedicated treatment lives in the [Xenobiology](../xenobiology/) entry. ## Adjacent and supporting fields Several adjacent and supporting scientific fields contribute to the broader life-engineering enterprise without belonging entirely to any of the four principal sub-disciplines. A brief survey clarifies the broader landscape. **Bioinformatics** is the computational discipline that handles biological sequence data, structural data, and the network-level relationships among biological components. Without contemporary bioinformatics, the petabyte-scale genome sequencing of the past two decades would have been useless; with it, the data become the substrate on which all subsequent life engineering operates. The field's tools — sequence-alignment algorithms, structural-prediction methods, network-analysis approaches — are the computational infrastructure of contemporary biology. **Systems biology** is the experimental and computational discipline that characterises biological systems at the network level — measuring all components simultaneously and modelling their interactions — as opposed to the reductionist gene-by-gene approach of earlier molecular biology. Systems biology provides the empirical foundation on which the engineering-discipline ambitions of synthetic biology depend. **Metabolic engineering** is the application of engineering principles to cellular metabolism — designing and optimising the chemical-reaction networks within cells for the production of specific molecules. Metabolic engineering is treated within both genetic engineering (as the longer-established empirical version) and synthetic biology (as the rationalised engineering-discipline version). **Protein engineering** is the design and modification of proteins for specific functions — through rational design (predicting structures and modifying them computationally), directed evolution (using laboratory selection to optimise function), or hybrid approaches. The 2024 Nobel Prize in Chemistry recognised David Baker's work on computational protein design (RFdiffusion and related methods) and Demis Hassabis and John Jumper's work on protein-structure prediction (AlphaFold) — three contributions that have transformed the protein-engineering side of life engineering across the past five years. **Directed evolution** is the application of selective-breeding methods at the molecular level — generating large populations of variant molecules and applying laboratory selection to enrich for desired functions. Frances Arnold shared the 2018 Nobel Prize in Chemistry for the development of directed evolution methods. **Tissue engineering** is the engineering discipline that produces functional biological tissues for medical, research, or industrial applications. Tissue engineering is increasingly converging with synthetic biology as both fields move toward the design of multicellular biological systems. **Biocomputing** is the use of biological systems to perform computation — either as a way of investigating biological information processing or as a practical alternative to silicon-based computing for specific applications. DNA storage of digital data (the Microsoft and other major-laboratory work since the late 2010s) is a particularly visible application. ## What life engineering currently does The scientific and industrial applications of life engineering have grown rapidly across the past two decades. The list below is partial and intended to convey the field's current operational scope rather than to be exhaustive. **In medicine**, life-engineered organisms produce a substantial fraction of the world's pharmaceutical insulin (a recombinant human protein produced in engineered bacteria or yeast), human growth hormone, erythropoietin, factor VIII for haemophilia, and a growing list of monoclonal antibodies for cancer, autoimmune disease, and infectious disease. CRISPR-based gene therapies for sickle-cell disease and beta-thalassaemia received regulatory approval in 2023. mRNA vaccine platforms, which the COVID-19 pandemic deployed at planetary scale, are a product of life-engineering capabilities. Engineered T-cells (CAR-T therapy) are an established treatment for several haematological cancers, with solid-tumour applications in active clinical development. Engineered viral vectors are the delivery mechanism for an expanding range of gene therapies for inherited and acquired diseases. **In agriculture**, transgenic crops — engineered for herbicide tolerance, insect resistance, drought tolerance, or nutritional fortification — occupy a large fraction of global commercial cropland. The acreage planted to transgenic varieties of soybean, maize, cotton, and canola is in the hundreds of millions of hectares annually. CRISPR-edited crops with smaller, more precise modifications than the earlier transgenic varieties are entering commercial use under more permissive regulatory frameworks in several jurisdictions. **In industrial production**, engineered microorganisms produce biofuels (engineered yeast for cellulosic ethanol; engineered algae for biodiesel), bioplastics (polyhydroxyalkanoates produced by engineered bacteria), industrial enzymes (proteases, amylases, lipases, cellulases used across the food, detergent, and biofuel industries), food ingredients (the Impossible Foods heme protein produced by engineered yeast; mycoprotein; precision-fermentation-produced dairy proteins), and an expanding list of fine chemicals previously sourced from petrochemical processes or rare natural sources. **In environmental applications**, bioremediation organisms engineered for the breakdown of specific pollutants (hydrocarbons, plastics, heavy metals), the sequestration of carbon dioxide, and the degradation of waste streams are at varying stages of development from laboratory demonstration to commercial deployment. **In foundational research**, the synthetic minimal cell and the directed-evolution platforms permit the systematic study of biological systems by construction rather than only by observation — the engineering-discipline epistemology, applied to life. The JCVI syn3A platform alone is in use at more than forty laboratories worldwide; the Sc2.0 synthetic-yeast consortium has involved researchers from at least a dozen institutions; the CRISPR toolkit has been adopted essentially universally across molecular biology. The pace is the relevant point. None of these capabilities existed in operational form fifty years ago. Most of them did not exist twenty years ago. Several of them did not exist five years ago. The cumulative growth rate is one of the structural features the framework's reading attends to. ## What life engineering does not yet do The field's limits are also worth registering, because they bound the framework's predicted convergence with the source material's account. Contemporary life engineering operates almost entirely at the level of *modifying existing organisms* and *constructing single-cell organisms from designed genomes*. The synthesis of a multicellular organism from designed DNA, beginning from a single synthesised cell, has not been achieved and is not currently within reach. The construction of an animal — let alone an intelligent animal — from designed DNA is not on the immediate research horizon for terrestrial life engineering. The capability the source material attributes to the Elohim — the species- and ecosystem-scale synthesis of complete multicellular life-forms, including humans — exceeds present-day terrestrial capability by an enormous margin. The specific limits worth noting: - **Multicellular design.** The transition from designed single cells to designed multicellular organisms remains a major open problem. Developmental biology — the discipline that studies how multicellular form emerges from cell-cell interactions during embryogenesis — has not yet yielded principles general enough to permit the design of multicellular form from scratch. The Xenobot work and other synthetic-developmental-biology programmes are early steps but remain far from the design of organised animal-scale multicellular life. - **Genome design at species scale.** Even at the single-cell level, the design of a wholly novel genome remains beyond current capability. The synthetic-genomics work to date — syn1.0 and its derivatives, the Sc2.0 work — synthesises *redesigned* versions of *existing* genomes rather than wholly novel ones. The de novo design of a viable genome from biochemical first principles has not been achieved. - **The function of essential genes.** As of the 2016 syn3.0 publication, approximately 30 percent of the genes essential for cellular life had no characterised function. Subsequent work has reduced this fraction but a substantial gap remains. A free-living organism whose every gene's function is fully understood — in the way an engineered system's every component is fully understood — does not yet exist. - **The interface between design and emergence.** Biological systems exhibit emergent properties — robustness, adaptability, self-organisation — that are not straightforward consequences of any designable component. The engineering-discipline ambition of synthetic biology runs into the persistent reality that living systems are far more than the sum of their designed parts, and the design rules for predictable emergence remain incomplete. - **Ecological-scale engineering.** The design of an ecosystem — multiple species, interacting through nutrient cycles, predator-prey relationships, and the broader webs that organise natural communities — is far beyond contemporary capability. The source material's account of the Elohim's work implies ecosystem-scale design (terrestrial flora and fauna as an integrated synthesised system); present-day life engineering does not approach this scale. The trajectory, however, is forward. The relevant question is not whether the present-day capability matches the source material's account (it does not) but whether the development is moving toward such a capability and at what rate. On both counts, the answer is conditionally affirmative: the capability is expanding, the cost is falling, the precision is increasing, the parts catalogue is growing, and the conceptual frameworks (synthetic genomics, synthetic biology, xenobiology) for thinking about life as something designable are now established within the scientific community. ## Open questions The field is in motion and several major scientific, ethical, and philosophical questions are unresolved. - **The function of the dark genome.** The fraction of any given genome — including the synthetic minimal cell — whose function remains uncharacterised is substantial. Even after a quarter-century of intensive characterisation, the human genome's regulatory architecture is incompletely mapped and the function of much non-coding DNA remains contested. - **The boundary between modification and creation.** Whether the synthetic minimal cell is genuinely a *created* life-form, whether it is merely a *re-engineered descendant* of a naturally evolved precursor (since syn1.0 was based on the existing *Mycoplasma mycoides* genome and syn3.0 was derived from syn1.0 through reduction), and whether the distinction is well-defined are contested questions within the field itself. The first genuinely *de novo* designed cellular life — built from biochemical first principles rather than from the editing of existing biology — has not been achieved. - **The transition to multicellularity.** How natural evolution made the transition from single-cell to multicellular life (an event in the deep evolutionary record that occurred multiple times independently) and how that transition might be engineered are open questions in both evolutionary biology and synthetic biology. - **Biosafety and dual use.** The same capabilities that permit the engineering of beneficial organisms permit the engineering of dangerous ones. The dual-use question — what to allow, what to restrict, what to require — is an active and unresolved area of policy debate at national and international levels. The 2002 Wimmer poliovirus synthesis demonstrated the capability twenty years before the regulatory frameworks caught up; comparable concerns now attend influenza, smallpox, and other potential pathogens. The biosecurity question is structurally connected to the broader political question of what oversight powerful technologies require. - **Germline modification of humans.** The He Jiankui case of 2018 demonstrated that human germline editing was technically feasible while producing a strong international scientific consensus that it should not be conducted clinically under present conditions. The longer-term question — whether, under what conditions, with what oversight, and for what indications human germline editing should be developed — is an open scientific, ethical, and political question. - **The philosophical status of designed life.** Whether designed life is the same kind of thing as evolved life, whether the engineering-discipline approach to biology will reach a regime in which the natural-evolved/designed distinction loses its current importance, and what the broader implications of these developments are for the human relationship to the natural world are questions debated across the philosophy of biology, the ethics of technology, and the broader humanistic literature. ## In the Wheel of Heaven framework The contemporary development of life engineering is, on the Wheel of Heaven reading, the framework's most concrete predicted convergence with the source material — the one most amenable to verification on a near-term human timeline and the one most directly recoverable from the source's own statements about what humanity would learn to do. ### The source material's account The source material's account of the Elohim's principal capability is specific. *The Book Which Tells the Truth* (Vorilhon, 1974), in its second chapter — the chapter Yahweh delivers as a corrected reading of Genesis — describes the work of the Elohim scientists as the design and synthesis of biological organisms at the molecular level. The successive *yamim* of Genesis 1 are read as the successive stages of this work: the survey of Earth, the engineering of the atmosphere, the synthesis of plants, the calibration of astronomical reference frames, the synthesis of marine and avian life, the synthesis of land animals, the synthesis of humans, and the seventh-day cessation of active synthesis. The work is described not in metaphorical or theological terms but in the operational vocabulary of laboratory research: design, synthesis, testing, propagation, environmental release. The Elohim scientists are described as having reached a level of technical and scientific knowledge prior to undertaking the Earth project, which Yahweh characterises to Vorilhon as "comparable to that which you will soon reach" — a remark that frames the analogy structurally rather than rhetorically. The detailed operational picture the source material develops includes the design of organisms at the level of DNA, the assembly of those designs into living cells, the release of those cells into appropriate environments, and the propagation of the resulting populations through ordinary biological reproduction. This is, in present-day terminology, the integrated capability that genetic engineering, synthetic biology, synthetic genomics, and xenobiology are collectively developing. The Elohim, on the source's account, possess the capability at species- and ecosystem-scale; present-day humanity possesses it at single-cell scale, with the trajectory pointing toward larger scales. ### The convergence as a structural observation The framework reads the convergence between the source's account and contemporary terrestrial capability as a structural observation about the relationship between the source material's predictions and the developmental trajectory of human science across the past fifty years. The observation has several specific components. **First, the source material's prediction was concrete rather than vague.** A prediction that humanity would develop "some impressive technology" by some unspecified future date would be unfalsifiable and uninteresting. The source's prediction is specifically that humanity would develop the capability to *design and synthesise life* — the precise capability the source attributes to the Elohim civilization. The development of life engineering matches this prediction at the level of the specific capability, not at the level of a general impression of technological advancement. **Second, the prediction's timing was specific.** The source material identifies the period of disclosure — the Aquarian transition — as the period during which humanity would reach the scientific maturity required for the framework's content to be evaluable on its own terms rather than as a matter of faith or testimony. The 1974 publication of *The Book Which Tells the Truth* and the 1973 Boyer–Cohen demonstration of recombinant DNA fall within months of each other; the half-century since has produced the capability the source described. The framework treats this temporal alignment as significant. A source material that, in 1974, predicted humanity's near-future development of biological-design capability would have been making a prediction whose terms were not yet fully visible at the time of the prediction itself. **Third, the prediction was specific about the developmental trajectory, not just the endpoint.** Yahweh's reported statement to Vorilhon — that the Elohim had reached "a level of technical and scientific knowledge, comparable to that which you will soon reach" — was made in 1973 to a French motoring journalist whose scientific background did not place him in a position to assess the meaning of the claim. The statement's content becomes legible only retrospectively, in the light of the subsequent fifty years of development. The framework reads this retrospective legibility as a structural feature of the prediction: the source's content was specific enough to be empirically meaningful, but its specific meaning required the subsequent scientific development to interpret. ### Three readings of the convergence The framework recognises three distinct readings of the convergence between contemporary life engineering and the source material's account. Each is set out below, with the corpus's adopted position registered at the close. **The coincidence reading** holds that the convergence is a coincidence of no special significance. Many predictions are made by many sources at many times; some of those predictions, by chance alone, will resemble subsequent developments. The Raëlian source material's prediction of human biological-design capability is, on this reading, one such fortunate coincidence — perhaps assisted by the general scientific atmosphere of the early 1970s, in which the implications of the Watson–Crick discovery of 1953 and the genetic-code work of the early 1960s were beginning to suggest the possibility of biological design — but without standing as independent evidence for the source's broader claims. This is, broadly, the reading that mainstream scientific commentary would adopt if it engaged the question at all. **The cultural-influence reading** holds that the convergence reflects Vorilhon's exposure to the scientific atmosphere of his time. Recombinant DNA was being discussed in French scientific journalism in 1973; the broader cultural awareness of biological design was rising; Vorilhon, even without specialist training, could have absorbed enough of this atmosphere to incorporate a plausible-sounding biological prediction into his account. On this reading, the convergence is not evidence for the source's broader claims but evidence for the source's cultural location at the moment of its production. This is the reading that historical-critical engagement with the Raëlian text would naturally develop. **The framework reading** holds that the convergence is what it appears to be: a substantive prediction from a source that was in a position to make such a prediction, validated by the subsequent development of human capability along the lines the source described. The framework reading does not depend on the coincidence and cultural-influence readings being disprovable in any strict sense — those readings can be sustained by sufficiently determined commitment to the alternative interpretation — but it treats the prediction's specificity, timing, and structural alignment with the source's broader account as evidence that the source was reporting something real rather than constructing plausible-sounding fiction. The corpus adopts the framework reading. The grounds for this adoption are not that the alternative readings have been refuted (they have not been and probably cannot be) but that the framework reading is the one that takes the source material seriously as a historical document making substantive claims, and that the subsequent fifty years of scientific development have produced exactly the trajectory the source described. The framework's other lines of evidence — the textual reading of the Hebrew Bible developed in the [Genesis](../genesis/) entry, the comparative analysis of ancient creation traditions, the chronological reading developed in the precessional-age entries — are integrated with the life-engineering convergence into a single overall reading that the corpus treats as more parsimonious than the available alternatives. ### The structural significance to the Aquarian transition The framework treats the contemporary emergence of life engineering as one of the structural features of the Aquarian-age transition itself. The Age the corpus identifies as the period of disclosure is also, on the framework's reading, the period in which humanity becomes capable of evaluating the source material's claims about the Elohim's work on its own terms rather than as a matter of faith or testimony. A civilisation that has not yet developed life-engineering capability has no operational basis for assessing the source's account of biological synthesis; a civilisation that has developed the capability does. The framework treats the present period as the first historical moment at which Earth's humanity is in a position to evaluate the source's account empirically — both by recognising that the capability the source describes is genuinely possible (which the synthetic minimal cell establishes) and by extrapolating from contemporary trajectory to the species- and ecosystem-scale capability the source attributes to the Elohim. The Aquarian transition, on the framework's reading, is not principally a matter of human spiritual or political development (although it includes those) but of human scientific development. The capability that distinguishes the post-Aquarian humanity from the pre-Aquarian humanity is the capability to take its place in the cosmic chain of creator civilisations — to become, in time, the next link in the chain that produced the Elohim and that the Elohim are in turn producing among the parallel humanities. The development of life engineering is the first concrete step along this path. The framework treats it as the empirical signature of the Aquarian transition's underlying reality. ### Specific source-text passages The Raëlian source material contains several specific passages bearing on the life-engineering convergence. They are not exhaustive but they establish the textual basis for the framework's reading. In *The Book Which Tells the Truth* (1974), Yahweh describes the Elohim scientists arriving on Earth and undertaking the synthesis of life: the work is described as carried out in laboratories adapted to the synthesis of organisms suited to the planetary conditions, with the synthesised life-forms released into the appropriate environments to propagate. The work is described in operational terms throughout: design at the molecular level, laboratory synthesis, environmental release, observation of propagation. The vocabulary is the vocabulary of contemporary biotechnology, not the vocabulary of religious creation narrative. Yahweh further describes the relationship between the Elohim's prior scientific development and humanity's anticipated future: a very long time ago on the Elohim's distant planet, the civilization had reached a level of technical and scientific knowledge comparable to what humanity would soon reach, with the early scientists creating primitive embryonic forms of life in laboratory conditions. The structural correspondence between this description and the contemporary state of synthetic biology is exact. Primitive embryonic forms of life in laboratory conditions is, in 1974 phrasing, the JCVI-syn3.0 minimal cell of 2016 — a primitive, minimal cellular life-form constructed in laboratory conditions. The match between the source's description of the Elohim's early state and humanity's current state is the specific convergence the framework reads as load-bearing. The source material also describes the eventual development of the program from the synthesis of primitive cellular life through more complex organisms to the species- and ecosystem-scale capability that produced the Earth project. The arc described in the source material — from minimal cell to ecosystem-scale design — is the developmental trajectory that contemporary terrestrial life engineering would have to traverse to reach the capability the Elohim are reported to possess. The corpus treats this as the framework's predicted trajectory for the post-Aquarian period of human development. ### Conditional and unconditional elements of the convergence The framework's reading distinguishes between what the convergence has settled and what it has not. **What the convergence has settled, on the framework's reading:** that the source material made a specific and substantive prediction about humanity's near-future developmental trajectory, and that the trajectory has unfolded in the predicted direction. This is a structural observation about the relationship between source-text and subsequent history; it does not depend on the framework's broader reading being correct. **What the convergence has not settled:** whether the source's account of the Elohim's own creative work, of which the present-day human capability is the convergent local instance, is itself historically accurate. The convergence establishes that the source predicted something real about humanity's future. It does not, on its own, establish that the source's account of the Elohim's past is equally real. That further question depends on additional lines of evidence the framework develops elsewhere — the textual readings of the Hebrew Bible and other ancient sources, the chronological readings of the precessional ages, the comparative readings of ancient creation traditions, and the broader synthesis the corpus develops across its full set of entries and the long-form chapter material. The treatment of the framework's overall evidential structure lives in the chapter material; the relevant chapters are the [Age of Aquarius](../timeline/age-of-aquarius/) chapter, which develops the broader picture of the Aquarian transition, and the [Apocalypse](../apocalypse/) entry, which treats the period of disclosure of which the life-engineering convergence is one of the structural elements. ## Comparative observations The framework's interest in the life-engineering convergence sits within a broader comparative landscape of how different traditions and modes of thought have approached the question of biological design. A brief survey clarifies the corpus's reading by contrast. ### The ancient-astronaut literature The broader ancient-astronaut interpretive tradition has, since von Däniken's *Chariots of the Gods?* (1968), attended to the question of whether the biological diversity of Earth could plausibly be a product of natural evolution alone or whether some form of intelligent design — by visiting non-terrestrial intelligences — is required. The corpus's reading is positioned within this broader tradition but is more specific in its claims and more disciplined in its sourcing. Where the broader ancient-astronaut literature has often treated biological design as a general hypothesis without specific developmental commitments, the corpus's reading treats it as a specific historical claim — the Earth project of c. 21,810 BCE through the present — supported by the convergence between contemporary human capability and the source material's account. The Sitchin tradition, in particular, has treated the Anunnaki of the Sumerian sources as the genetic engineers of humanity through the modification of an existing hominid stock — a position that differs from the framework's reading in several respects. The framework treats the synthesis of all terrestrial life as the Elohim's work rather than only the modification of pre-existing hominids; the framework reads the temporal placement of human creation in the Age of Leo (c. 11,375 BCE) rather than in the much earlier period Sitchin assigns; and the framework's reading is grounded in the Raëlian source material as primary text rather than in the Sumerian sources read through Sitchin's particular interpretive lens. ### Intelligent-design positions in mainstream discourse Within mainstream Western discourse, the "intelligent design" movement — principally associated with the Discovery Institute and figures such as Michael Behe, William Dembski, and Stephen Meyer — has argued that the complexity of biological systems exceeds what natural evolutionary processes can plausibly produce and therefore requires an intelligent designer. The framework's relationship to this position is complex. The framework agrees with the intelligent-design position that biological complexity points to design rather than to undirected evolution alone, but identifies the designer specifically as the Elohim civilization rather than as the supernatural deity the intelligent-design movement typically intends. The framework's reading is therefore aligned with the empirical observations on which the intelligent-design movement draws while differing from it in the ontological identification of the designer. The contemporary development of life engineering is, on the framework's reading, indirect support for the design-position empirical observations: humans, working as designers of biological systems, are now beginning to recognise from the inside how difficult and how design-intensive the production of even minimal cellular life is. The 30 percent of uncharacterised essential genes in the syn3.0 minimal cell is, on the framework's reading, a marker of how much purposeful design is embedded in any functional biological system. The framework treats this as evidence for design without thereby committing to the supernatural-designer identification. ### Mainstream evolutionary biology The mainstream evolutionary-biology position — that the diversity of terrestrial life is the product of natural selection acting on undirected variation across approximately 3.8 billion years — is the standard scientific account against which any design hypothesis must be measured. The framework's reading does not deny natural selection or the broader evolutionary mechanisms; it embeds them within a longer-arc account in which the Elohim's initial synthesis of terrestrial life established the conditions under which subsequent evolution operated, with periodic interventions across the 22,000-year project history. The framework treats natural selection as the principal mechanism by which the synthesised life diversified after the initial creation period — a position that combines design at the origin with natural evolution thereafter. This combination distinguishes the framework's reading from both the strict evolutionary position (no design) and the young-Earth creationist position (design with no significant subsequent evolution). The convergence with life engineering is relevant to this combined position. The contemporary development of life engineering establishes that biological design is possible — that it is the kind of thing intelligences can do — without thereby establishing that all life is designed or that natural evolution does not occur. The framework's reading accepts the design possibility (now demonstrated by life engineering at small scale) and the evolution reality (established by the mainstream biological literature) and proposes a historical reconstruction that integrates both. ### The Sendy tradition Within the specific Sendy–Raëlian interpretive tradition that the corpus reads as its principal scholarly antecedent, the framework's reading of the life-engineering convergence is consistent with Sendy's own reading and develops it forward. Sendy, writing in 1968–1974, did not have the benefit of the subsequent fifty years of scientific development; his identification of the Elohim as biological engineers was based on the textual evidence of Genesis read through the philological-historiographic methods he favoured. The subsequent development of life engineering vindicates Sendy's reading in the specific sense that the capability he attributed to the Elohim has now been partially demonstrated by terrestrial human science — the kind of vindication a philological reconstruction is positioned to receive from independent empirical developments. The framework's reading therefore positions Sendy's textual work, the Raëlian source material, and the contemporary scientific development of life engineering as three convergent lines of evidence on the same underlying claim. The independence of the three lines — Sendy worked from text, Vorilhon reports first-hand contact, contemporary science works from empirical investigation — is one of the structural features the framework reads as significant. ### Philip Ball and the new biology The work of the contemporary science writer **Philip Ball**, particularly in *How Life Works: A User's Guide to the New Biology* (2023), develops a synthesis of contemporary biological science that is relevant to the framework's reading. Ball's central argument is that the gene-centred view of biology that dominated the late twentieth century is inadequate to the complexity of how living systems actually function — that genes are one component among many in a richer architecture of cellular and organismal organisation, and that the contemporary understanding of biology is converging on a view in which design, organisation, and emergent function are properly recognised as central rather than incidental. The framework's reading is consistent with the direction of Ball's argument. The 30 percent of uncharacterised essential genes in the syn3.0 minimal cell, the complexity of multicellular development, the irreducibility of biological function to gene-by-gene analysis — these are features of the empirical picture that Ball's synthesis captures. The framework treats Ball's *How Life Works* as the most accessible contemporary synthesis of the scientific picture against which the life-engineering convergence is to be evaluated. Ball does not endorse the framework's broader reading, and the corpus does not claim him as a framework proponent. What the corpus does claim is that the contemporary scientific picture Ball synthesises is the picture the framework's reading of the life-engineering convergence depends on. ## See also - [Genesis](../genesis/) - [Genetic engineering](../genetic-engineering/) - [Synthetic biology](../synthetic-biology/) - [Synthetic genomics](../synthetic-genomics/) - [Xenobiology](../xenobiology/) - [Elohim](../elohim/) - [Tree of Life](../tree-of-life/) - [Age of Aquarius](../timeline/age-of-aquarius/) - [Age of Leo](../timeline/age-of-leo/) - [Apocalypse](../apocalypse/) - [Cosmic Chain](../cosmic-chain/) - [Cosmic Competition](../cosmic-competition/) - [Council of the Eternals](../council-of-eternals/) - [Embassy](../embassy/) - [Golden Age](../golden-age/) - [Jean Sendy](../jean-sendy/) - [Raël](../rael/) - [*Message from the Designers*](../library/message-from-the-designers/) - [Mauro Biglino](../mauro-biglino/) - [Paul Anthony Wallis](../paul-anthony-wallis/) ## References Vorilhon, Claude (Raël). *The Book Which Tells the Truth* (1974) and *Extraterrestrials Took Me to Their Planet* (1976), collected as *Message from the Designers* (Raëlian Foundation, current English edition). Sendy, Jean. *La Lune, clé de la Bible*. Julliard, 1968. Sendy, Jean. *Ces dieux qui firent le ciel et la terre*. Robert Laffont, 1969. English: *Those Gods Who Made Heaven and Earth*. Berkley, 1972. Ball, Philip. *How Life Works: A User's Guide to the New Biology*. Picador / University of Chicago Press, 2023. Watson, James D., and Francis H. C. Crick. "Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid." *Nature* 171 (1953): 737–738. Jackson, David A., Robert H. Symons, and Paul Berg. "Biochemical Method for Inserting New Genetic Information into DNA of Simian Virus 40." *Proceedings of the National Academy of Sciences* 69 (1972): 2904–2909. Cohen, Stanley N., Annie C. Y. Chang, Herbert W. Boyer, and Robert B. Helling. "Construction of Biologically Functional Bacterial Plasmids in Vitro." *Proceedings of the National Academy of Sciences* 70 (1973): 3240–3244. Sanger, Fred, S. Nicklen, and A. R. Coulson. "DNA Sequencing with Chain-Terminating Inhibitors." *Proceedings of the National Academy of Sciences* 74 (1977): 5463–5467. Mullis, Kary B., et al. "Specific Enzymatic Amplification of DNA in Vitro: The Polymerase Chain Reaction." *Cold Spring Harbor Symposia on Quantitative Biology* 51 (1986): 263–273. Elowitz, Michael B., and Stanislas Leibler. "A Synthetic Oscillatory Network of Transcriptional Regulators." *Nature* 403 (2000): 335–338. [The repressilator.] Gardner, Timothy S., Charles R. Cantor, and James J. Collins. "Construction of a Genetic Toggle Switch in Escherichia coli." *Nature* 403 (2000): 339–342. [The toggle switch.] Cello, Jeronimo, Aniko V. Paul, and Eckard Wimmer. "Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template." *Science* 297 (2002): 1016–1018. Gibson, Daniel G., et al. "Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome." *Science* 329 (2010): 52–56. [JCVI-syn1.0.] Jinek, Martin, Krzysztof Chylinski, Ines Fonfara, Michael Hauer, Jennifer A. Doudna, and Emmanuelle Charpentier. "A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity." *Science* 337 (2012): 816–821. [The CRISPR–Cas9 foundational paper.] Hutchison, Clyde A., III, et al. "Design and Synthesis of a Minimal Bacterial Genome." *Science* 351 (2016): aad6253. [JCVI-syn3.0.] Pelletier, James F., et al. "Genetic Requirements for Cell Division in a Genomically Minimal Cell." *Cell* 184 (2021): 2430–2440. [JCVI-syn3A.] Pinheiro, Vitor B., et al. "Synthetic Genetic Polymers Capable of Heredity and Evolution." *Science* 336 (2012): 341–344. [Xeno-nucleic acids.] Malyshev, Denis A., et al. "A Semi-Synthetic Organism with an Expanded Genetic Alphabet." *Nature* 509 (2014): 385–388. [Romesberg group, unnatural base pairs.] Anzalone, Andrew V., et al. "Search-and-Replace Genome Editing without Double-Strand Breaks or Donor DNA." *Nature* 576 (2019): 149–157. [Prime editing.] Hanczyc, Martin M. "Engineering Life: A Review of Synthetic Biology." *Artificial Life* 26, no. 2 (2020): 260–273. Andrianantoandro, Ernesto, Subhayu Basu, David K. Karig, and Ron Weiss. "Synthetic Biology: New Engineering Rules for an Emerging Discipline." *Molecular Systems Biology* 2 (2006): 0028. Endy, Drew. "Foundations for Engineering Biology." *Nature* 438 (2005): 449–453. Church, George M., et al. "Next-Generation Digital Information Storage in DNA." *Science* 337 (2012): 1628. Jumper, John, et al. "Highly Accurate Protein Structure Prediction with AlphaFold." *Nature* 596 (2021): 583–589. Watson, Joseph L., et al. "De Novo Design of Protein Structure and Function with RFdiffusion." *Nature* 620 (2023): 1089–1100. J. Craig Venter Institute. "First Minimal Synthetic Bacterial Cell." National Human Genome Research Institute. "Synthetic Biology." Royal Society. *Synthetic Biology: Scientific Discussion Meeting Report*. 2008. National Academies of Sciences, Engineering, and Medicine. *Biodefense in the Age of Synthetic Biology*. National Academies Press, 2018. "Synthetic biology." *Wikipedia*. "Genetic engineering." *Wikipedia*. "Synthetic genomics." *Wikipedia*. "Xenobiology." *Wikipedia*. "CRISPR." *Encyclopaedia Britannica*.